Vycor Medical, Inc. VYCO
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -210.95% | 132.06% | -1,379.59% | -79.50% | 161.92% |
| Total Depreciation and Amortization | -8.28% | -2.48% | 1.26% | 6.00% | -6.83% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -98.95% | 3,066.67% | -98.00% | -18.92% | 0.54% |
| Change in Net Operating Assets | -94.46% | -36.61% | 179.02% | -901.85% | 52.63% |
| Cash from Operations | -104.83% | 153.57% | 154.14% | -255.36% | 273.23% |
| Capital Expenditure | -- | -- | -- | 100.00% | -- |
| Sale of Property, Plant, and Equipment | -85.71% | -- | -- | -100.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -85.71% | 231.25% | -- | 100.00% | -- |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | 31.54% | 0.00% | 32.58% | -325.00% | 70.62% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 31.54% | 0.00% | -140.27% | 811.54% | 70.62% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -116.96% | 280.26% | 164.23% | -191.73% | 186.77% |